Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018204477) METHODS AND REAGENTS FOR TUMOR TARGETING WITH GREATER EFFICACY AND LESS TOXICITY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/204477 International Application No.: PCT/US2018/030620
Publication Date: 08.11.2018 International Filing Date: 02.05.2018
IPC:
A61K 39/395 (2006.01) ,A61K 47/64 (2017.01) ,A61K 47/66 (2017.01) ,A61K 47/68 (2017.01) ,A61K 51/00 (2006.01) ,A61K 51/08 (2006.01) ,A61K 51/10 (2006.01) ,C07K 16/18 (2006.01) ,C07K 16/28 (2006.01) ,C07K 16/30 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
[IPC code unknown for A61K 47/64][IPC code unknown for A61K 47/66][IPC code unknown for A61K 47/68]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51
Preparations containing radioactive substances for use in therapy or testing in vivo
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51
Preparations containing radioactive substances for use in therapy or testing in vivo
02
characterised by the carrier
04
Organic compounds
08
Peptides, e.g. proteins
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51
Preparations containing radioactive substances for use in therapy or testing in vivo
02
characterised by the carrier
04
Organic compounds
08
Peptides, e.g. proteins
10
Antibodies or immunoglobulins; Fragments thereof
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
Applicants:
CORNELL UNIVERSITY [US/US]; Center for Technology Licensing at Cornell University (CTL) 395 Pine Tree Road, Suite 310 Ithaca, NY 14850, US
Inventors:
BANDER, Neil H.; US
Agent:
GOLDMAN, Michael L.; US
KEYS, Amanda, L.; US
MERKEL, Edwin, V.; US
TISCHNER, Tate, L.; US
O'GARA, Megan, T.; US
CHILDS, Carissa, R.; US
Priority Data:
62/500,18702.05.2017US
Title (EN) METHODS AND REAGENTS FOR TUMOR TARGETING WITH GREATER EFFICACY AND LESS TOXICITY
(FR) PROCÉDÉS ET RÉACTIFS POUR CIBLAGE DE TUMEUR AVEC UNE EFFICACITÉ AMÉLIORÉE ET UNE TOXICITÉ RÉDUITE
Abstract:
(EN) The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and/or pharmacokinetics. The first and second agents are administered to a subject having cancer to treat the cancer. Also disclosed is a combination therapeutic comprising the first and second agents.
(FR) La présente invention concerne un procédé de traitement d'un cancer. Ce procédé comprend la fourniture d'un premier agent comprenant un premier composant de ciblage couplé à un premier composant thérapeutique anticancéreux et la fourniture d'un deuxième agent comprenant un deuxième composant de ciblage couplé à un deuxième composant thérapeutique anticancéreux. Les premier et deuxième composants de ciblage ont des biodistributions et/ou pharmacocinétiques différentes. Les premier et deuxième agents sont administrés à un sujet atteint d'un cancer pour traiter le cancer. L'invention concerne en outre un produit thérapeutique d'association comprenant les premier et deuxième agents.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)